MLchartDataset catalogue

DNA plasmid vaccine ITI-1001

Term · Oncology and biomedicine · MLC-T-ONC-013095

An off-the-shelf (OTS) plasmid DNA cancer vaccine containing two DNA plasmids, one encoding for the two human cytomegalovirus (CMV) antigens immediate-early 1 (IE-1) and the matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) fused to the lysosome-associated membrane protein 1 (LAMP-1), and one plasmid encoding for the CMV glycoprotein B (gB) antigen which is also fused to LAMP-1, with potential immunomodulating and antineoplastic activities, Upon intramuscular (IM) administration and following electroporation, the DNA plasmid vaccine ITI-1001 is taken up by antigen presenting cells (APCs) and transported via LAMP-1 and the lysosome-mediated pathway. This results in enhanced major histocompatibility (MHC) class II antigen presentation of the three antigens to the immune system, thereby promoting CD4-positive T-cell responses as well as CD8-positive T-cell responses against tumor cells expressing the three viral antigens. IE1, pp65 and gB are expressed in certain tumor types. The incorporation of LAMP-1 routes the CMV antigens into the lysosomal compartment.

Table 1. Record
IdentifierMLC-T-ONC-013095
FieldOncology and biomedicine
SynonymsCMV antigens vaccine ITI-1001; DNA vaccine ITI-1001; IE-1/pp65/gB-encoding pDNA vaccine ITI-1001; pDNA Vaccine ITI-1001
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013095",
  "term": "DNA plasmid vaccine ITI-1001",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf (OTS) plasmid DNA cancer vaccine containing two DNA plasmids, one encoding for the two human cytomegalovirus (CMV) antigens immediate-early 1 (IE-1) and the matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) fused to the lysosome-associated membrane protein 1 (LAMP-1), and one plasmid encoding for the CMV glycoprotein B (gB) antigen which is also fused to LAMP-1, with potential immunomodulating and antineoplastic activities, Upon intramuscular (IM) administration and following electroporation, the DNA plasmid vaccine ITI-1001 is taken up by antigen presenting cells (APCs) and transported via LAMP-1 and the lysosome-mediated pathway. This results in enhanced major histocompatibility (MHC) class II antigen presentation of the three antigens to the immune system, thereby promoting CD4-positive T-cell responses as well as CD8-positive T-cell responses against tumor cells expressing the three viral antigens. IE1, pp65 and gB are expressed in certain tumor types. The incorporation of LAMP-1 routes the CMV antigens into the lysosomal compartment.",
  "synonyms": [
    "CMV antigens vaccine ITI-1001",
    "DNA vaccine ITI-1001",
    "IE-1/pp65/gB-encoding pDNA vaccine ITI-1001",
    "pDNA Vaccine ITI-1001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dna-plasmid-vaccine-iti-1001/"
}

Record 6,112 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.